#USA #Citius Pharma #Cranford #LYMPHIR #Citius Oncology

Citius Pharmaceuticals, Inc. Shows Positive Growth in Q3 2026

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) has announced remarkable financial outcomes for the third quarter of fiscal 2026, showcasing the company's commitment to developing innovative biopharmaceuticals. As of June 30, 2026, Citius has reported an impressive revenue total of $7.1 million for the first nine months of the fiscal year, largely attributed to the commercial sales of its targeted immunotherapy product, LYMPHIR.

Financial Overview

The figures presented in the earnings report demonstrate a strong financial footing, with cash and cash equivalents amounting to $17 million. The company emphasizes the robust growth experienced following its LYMPHIR launch, which is gaining traction across various medical institutions. In particular, LYMPHIR is now available at 44 prominent academic oncology centers, as well as National Comprehensive Cancer Network (NCCN) institutions and community infusion centers.

Lenard Mazur, Chairman and CEO of Citius Pharma and Citius Oncology, expressed optimism regarding this growth, noting an 80% increase in new institutional orders and a 31% rise in wholesale vial orders. Such advancements reflect an uptick in clinical familiarity and acceptance among healthcare providers.

Business Update

Citius Pharma's business strategies include further expansion of its commercial and medical affairs teams. Recently, the organization has seen an increase of 29 professionals within these teams, aimed at enhancing patient support services, marketing strategies, and engagement with key oncology treatment centers. This revamped structure is expected to improve formulary adoption and expand access to eligible patients as the company progresses with its launch strategy.

Furthermore, the company is actively developing the long-term value of LYMPHIR through ongoing clinical trials. Recent Phase 1 data presented at the 2026 ASCO Annual Meeting showcased promising results of LYMPHIR used in combination with pembrolizumab for treating recurrent gynecologic malignancies, demonstrating a 24% overall response rate and a median progression-free survival of 20.5 months for patients who benefited. Additionally, for high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a staggering 86% objective response rate was reported after using LYMPHIR prior to CAR-T therapy.

Revenue Insights

The financial report highlights revenue growth in more detail, capturing $1.5 million for the quarter ended June 30, 2026, which is an increase from no revenue during the same quarter in the previous fiscal year. Citius Pharma achieved a gross profit of $1 million, indicative of a gross margin of about 67% for the quarter. However, the net loss applicable to common stockholders of $8.9 million, or $(0.34) per share, poses considerations as it compares similarly to the previous year. Meanwhile, the overall revenue for the nine-month period ended June 30, 2026, reaches $7.1 million, indicating solid growth potential for the company as it continues to carve a niche in the competitive pharmaceutical landscape.

Strategic Growth and Future Outlook

As Citius Pharmaceuticals looks ahead, the focus remains on disciplined execution and efficient scaling. The company is preparing for a significant launch of its key products, including Mino-Lok® and Halo-Lido, both of which target critical care needs and show potential market relevance. With an increasing commitment to R&D, enhanced partnerships, and a solid financial trajectory, Citius Pharma aims to maximize its opportunities within the growing oncology market.

In summary, the third-quarter results and strategic updates paint a positive picture for Citius Pharmaceuticals as it seeks to innovate and deliver impactful cancer therapies. The teamwork and defined strategies around LYMPHIR will likely play a pivotal role in the company's future successes.